With the increasing use of minimally-invasive surgeries (‘keyhole’; ‘MIS’), many fields of surgery rely on video X-ray imaging to guide procedures. But these real-time 2D X-ray images do not show soft tissues or 3D information clearly. This lack of accurate perception has several negative impacts for patients: longer procedure time, greater use of kidney-toxic iodine dyes (the leading cause of kidney failure in hospitals), lower overall accuracy and poorer patient outcomes.

Cydar’s innovative software technology fuses CT scan data with standard X-ray guidance imaging to give physicians a real time 3D view of the anatomy. Their patent-protected methods and cloud platform enable physicians to operate more effectively in the operating room while saving time, reducing radiation exposure and improving patient outcomes. Using only video feeds generated by the X-ray machine, Cydar can be used in virtually any operating room with little added hardware.

Founded by endovascular aortic surgeon Tom Carrell and radiology scientist Graeme Penney, Cydar won the Cambridge News Business Innovation Award 2018 and was listed by Forbes as one of four British medical start-ups to watch in 2018.

Their endovascular solution, which has been approved by NHS Digital and is CE marked and FDA cleared, is currently in 4 commercial test sites in the UK and US. The company is backed by GSTC Health Innovations, Cambridge Capital Group, Guy’s and St Thomas’ Charity and King’s College London.

 

Investment Highlights

  • $3bn addressable market for Cydar image fusion technology.

  • Impressive board and management team composed of 7 PhDs led by Tom Carrell.

  • Early traction in the UK and US where the company has obtained CE marking and FDA clearance.

  • Patent-protected technology that allows surgeons to operate more effectively and cost efficiently in the operating room.

  • Supportive shareholder base including Guy’s and St Thomas' Charity, King’s College London and Cambridge Capital Group.